会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Biomarker isolation and use thereof to characterize physiological state
    • 生物标志物分离及其用于表征生理状态
    • US07794952B2
    • 2010-09-14
    • US11639414
    • 2006-12-15
    • Lance LiottaEmanuel Petricoin
    • Lance LiottaEmanuel Petricoin
    • G01N33/53
    • G01N33/6848G01N33/57415G01N33/57449G01N2333/4703G01N2333/976G01N2400/02
    • The present invention relates to compositions and methods for characterizing the physiological state of a living system, including cells, tissues, organs, and whole organisms. The methods involve capturing biomarkers from the living system, and correlating their presence or absence to a physiological state. The biomarkers can be captured from the system, and then detected using any suitable analytical system to determine their presence or absence. In one embodiment, the invention relates to a method of detecting a polypeptide biomarker in a blood serum or plasma sample obtained from a single subject with an affinity ligand which is capable of binding to a plurality of different polypeptide biomarkers derived from the same parental molecule.
    • 本发明涉及用于表征生物体系的生理状态的组合物和方法,包括细胞,组织,器官和整个生物体。 该方法涉及从生物系统捕获生物标志物,并将其存在或不存在与生理状态相关联。 生物标志物可以从系统中捕获,然后使用任何合适的分析系统进行检测以确定其存在或不存在。 在一个实施方案中,本发明涉及一种检测从单个受试者获得的血清或血浆样品中的多肽生物标志物的方法,该亲和配体能够结合来自同一亲本分子的多种不同的多肽生物标志物。
    • 8. 发明申请
    • Identification and Treatment of Aggressive Lung Cancer Tumors
    • 侵袭性肺癌肿瘤的鉴别与治疗
    • US20110318336A1
    • 2011-12-29
    • US13075163
    • 2011-03-29
    • Emanuel Petricoin, IIIJulia WulfkuhleAngela Zupa
    • Emanuel Petricoin, IIIJulia WulfkuhleAngela Zupa
    • A61K39/395A61K31/517A61P35/00A61K31/506A61K31/404C40B40/10C40B30/04A61K31/5377
    • G01N33/6884A61K31/00G01N33/57423G01N2800/02
    • This invention relates to the identification and treatment of aggressive lung cancer tumors in patients. More particularly, it provides a method of identifying patients with non-small cell lung carcinoma (NSCLC) who have an aggressive node-negative (N0) tumor and a likelihood of a poor overall survival. The method comprises the step of determining if one or more of certain identified proteins are activated in tumor cells obtained from the patient's tumor, wherein the activation of one or more of the proteins indicates that the patient has an aggressive N0 tumor and is likely to have a poor overall-survival. The invention also provides a method for selecting a treatment for an NSCLC patient with an N0 tumor and a method for treating such patients. It further provides a kit for identifying an NSCLC patient with an aggressive N0 tumor and a likelihood of a poor overall survival and a pharmaceutical composition for treating such patients.
    • 本发明涉及患者侵袭性肺癌肿瘤的鉴别和治疗。 更具体地,其提供了鉴定具有侵袭性淋巴结阴性(N0)肿瘤和总生存差的可能性的非小细胞肺癌(NSCLC)患者的方法。 该方法包括确定某些鉴定的蛋白质中的一种或多种是否在从患者肿瘤获得的肿瘤细胞中被活化的步骤,其中一种或多种蛋白质的活化指示患者具有侵略性的N0肿瘤并且可能具有 总体生存差 本发明还提供了用于选择具有N0肿瘤的NSCLC患者的治疗方法和用于治疗这种患者的方法。 它进一步提供了一种用于鉴定具有侵袭性N0肿瘤的NSCLC患者和总体存活差的可能性的试剂盒和用于治疗这种患者的药物组合物。